Clinical Trials Logo
  1. Home
  2. SLE
  3. NCT05966480

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus — LUMUS  

SLE Clinical Trial

Official title:
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients With Systemic Lupus Erythematosus

Clinical Trial Summary

The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.

Clinical Trial Description

This study will consist of a 5 week screening period, 48 week treatment period, and a 4 week follow up period for a total of 57 weeks. Each participant will be randomized to receive ESK-001 or placebo for 48 weeks. An open label extension study will be available for those patients who complete the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05966480
Study type Interventional
Source Alumis Inc
Contact Central Recruiting
Phone (+1) 650-538-2502
Email clinicaltrials@alumis.com
Status Recruiting
Phase Phase 2
Start date June 26, 2023
Completion date December 1, 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05479071 - Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
Completed NCT02240888 - Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response N/A
Active, not recruiting NCT05748925 - Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients Phase 4
Not yet recruiting NCT04517240 - A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus
Completed NCT00710021 - Vitamin D3 in Systemic Lupus Erythematosus Phase 2
Terminated NCT01946880 - Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) Phase 2
Active, not recruiting NCT04018222 - Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
Completed NCT03240536 - Choosing Tests Wisely in Rheumatology N/A
Completed NCT04368299 - Telemedicine for Follow-up of Systemic Lupus Erythematosus N/A
Active, not recruiting NCT04037293 - Premature Atherosclerosis in Systemic Lupus Erythematosus
Not yet recruiting NCT04234633 - Effect of Gender on Clinical Presentation of SLE ِAt Assiut University Hospitals
Completed NCT01207297 - Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis Phase 1
Terminated NCT00152555 - Physical Therapy for Systemic Lupus Erythematosus (SLE) N/A
Recruiting NCT05822219 - Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases N/A
Completed NCT04806113 - COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases Phase 3
Completed NCT03155477 - Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D N/A
Recruiting NCT05342285 - Flow Mediated Dilation in Association With Hyperuricemia
Not yet recruiting NCT03984227 - New Signaling Pathway Targeting Systemic Lupus Erythematosus
Enrolling by invitation NCT03144063 - Improving the Assessment of SLE Disease Activity N/A
Active, not recruiting NCT01761422 - Myocardial Inflammation in Systemic Lupus Erythematosus